- Home
- DOW vs INSM Comparison
DOW vs INSM Comparison
Compare DOW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOW
- INSM
- Stock Information
- Founded
- DOW 1897
- INSM 1988
- Country
- DOW United States
- INSM United States
- Employees
- DOW N/A
- INSM N/A
- Industry
- DOW Major Chemicals
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- DOW Industrials
- INSM Health Care
- Exchange
- DOW Nasdaq
- INSM Nasdaq
- Market Cap
- DOW 19.0B
- INSM 19.1B
- IPO Year
- DOW N/A
- INSM 2000
- Fundamental
- Price
- DOW $29.66
- INSM $99.11
- Analyst Decision
- DOW Hold
- INSM Strong Buy
- Analyst Count
- DOW 15
- INSM 17
- Target Price
- DOW $35.40
- INSM $108.07
- AVG Volume (30 Days)
- DOW 13.8M
- INSM 5.0M
- Earning Date
- DOW 07-24-2025
- INSM 08-07-2025
- Dividend Yield
- DOW 9.47%
- INSM N/A
- EPS Growth
- DOW N/A
- INSM N/A
- EPS
- DOW 0.40
- INSM N/A
- Revenue
- DOW $42,630,000,000.00
- INSM $381,030,000.00
- Revenue This Year
- DOW N/A
- INSM $28.03
- Revenue Next Year
- DOW $3.06
- INSM $120.54
- P/E Ratio
- DOW $74.20
- INSM N/A
- Revenue Growth
- DOW N/A
- INSM 20.77
- 52 Week Low
- DOW $25.06
- INSM $60.40
- 52 Week High
- DOW $55.97
- INSM $106.83
- Technical
- Relative Strength Index (RSI)
- DOW 54.83
- INSM 62.52
- Support Level
- DOW $27.09
- INSM $95.27
- Resistance Level
- DOW $30.93
- INSM $98.53
- Average True Range (ATR)
- DOW 1.06
- INSM 2.77
- MACD
- DOW 0.31
- INSM -1.45
- Stochastic Oscillator
- DOW 70.55
- INSM 34.45
About DOW Dow Inc.
Dow Chemical is a diversified global chemicals producer, formed in 2019 as a result of the DowDuPont merger and subsequent separations. The firm is a leading producer of several chemicals, including polyethylene, ethylene oxide, and silicone rubber. Its products have numerous applications in both consumer and industrial end markets.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.